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Objective: This study was undertaken to examine the causes of late aortic insuffi-
ciency in patients who had aortic valve replacement with the Toronto SPV biopros-
thesis (St Jude Medical, Inc, St Paul, Minn).
Methods: From 1991 to 1996, 174 patients with a mean age of 63 ± 11 years under-
went aortic valve replacement with the Toronto SPV bioprosthesis and were evalu-
ated annually by Doppler echocardiographic studies to assess valve function. The
diameters of the aortic root were retrospectively measured in all patients who had
aortic insufficiency and also in a random sample of 23 patients without aortic insuf-
ficiency. The mean follow-up was 5.8 years (range 4 to 9 years).
Results: Aortic insufficiency greater than 1+ developed in 19 patients. The diame-
ter of the sinotubular junction increased in these patients and did not change in those
without aortic insufficiency. The ratio between the diameter of the sinotubular junc-
tion and the size of the Toronto SPV bioprosthesis increased in patients who had
aortic insufficiency and did not change in those without aortic insufficiency. Both
2-way analysis of covariance and analysis by a mixed linear model demonstrated a
significant difference in slopes between the patients with aortic insufficiency
greater than 1+ and in those without insufficiency for the ratio of the diameter of
the sinotubular junction/diameter of the Toronto SPV relationships over time (aor-
tic insufficiency · Year; P < .001). Structural valve deterioration was observed in 5
valves, and in 4 of them the sinotubular junction of the aortic root had dilated. The
freedom from structural valve deterioration was 99% ± 1% for patients without aor-
tic insufficiency and 82% ± 12% for those with aortic insufficiency of more than 1+
at 8 years (P = .004). One patient had moderate aortic insufficiency without struc-
tural valve deterioration and dilation of the sinotubular junction.
Conclusions: Dilation of the sinotubular junction causes aortic insufficiency after
aortic valve replacement with the Toronto SPV bioprosthesis and increases the risk
of structural valve deterioration. Banding the sinotubular junction may prevent dila-
tion and enhance the durability of this valve.
Dilation of the sinotubular junction causes aortic insufficiency (AI)in patients with normal aortic cusps.1,2 This is the mechanism ofAI in patients with ascending aortic aneurysm and anatomicallynormal aortic cusps and the reason replacement of the ascendingaorta with proper reduction in the diameter of the sinotubularjunction corrects AI in these patients.1,3,4 Dilation of the sino-
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tubular junction occurs in patients with diseased media of
the ascending aorta such as those with bicuspid aortic valve,
systemic hypertension, and in some older patients.5,6
Aortic valve replacement (AVR) with stentless biologic
valves (pulmonary autograft, aortic valve homograft, and
porcine aortic valves) is performed by implanting the donor
valve in the subcoronary position of the recipient’s aortic
root or by using it as an aortic root either inside the native
aortic root (inclusion technique) or as a full aortic root
replacement.1 When the technique of subcoronary implanta-
tion is used, it is extremely important that the diameter of
the sinotubular junction of the recipient’s aortic root be sim-
ilar to that of the donor valve at the end of the procedure.1
Although intraoperative correction of the diameter of the
sinotubular junction of the recipient’s aortic root allows for
proper coaptation of the cusps and valve competence, there
is no guarantee that the diameter of the sinotubular junction
will remain unchanged for the life of the stentless biologic
valve. Progressive dilation of the sinotubular junction pulls
the cusps apart, increases the mechanical stress, and may
cause premature failure of the stentless valve.
This study examines the correlation between dilation of
the sinotubular junction and AI after AVR with the Toronto
SPV bioprosthesis (St Jude Medical, Inc, St Paul, Minn).
Patients and Methods
From July 1991 to June 1996, 174 patients underwent isolated
AVR with the Toronto SPV bioprosthesis at Toronto General
Hospital as part of a multicenter, observational trial sponsored by
St Jude Medical to obtain Food and Drug Administration approval
for this valve. The Toronto SPV bioprosthesis was approved late in
1997, but all patients have continued to be monitored annually
with clinical evaluations and Doppler echocardiographic studies.
The selection of size of the Toronto SPV bioprosthesis was
based on the diameter of the sinotubular junction. If the diameter
of the sinotubular junction was more than 2 mm larger than the
diameter of aortic anulus, this valve was not used in this trial.
Bioprosthetic aortic valve function was assessed by transtho-
racic Doppler echocardiography 1 week after the operation, 3 to 6
months postoperatively, and annually thereafter. Peak and mean
systolic flow velocity across the aortic valve was recorded with
continuous-wave Doppler ultrasonography and also proximal to
the aortic valve with pulsed-wave Doppler ultrasonography. The
diameter of the left ventricular outflow tract was measured in
midsystole from the parasternal long-axis view to calculate the
effective aortic valve area and cardiac output. AI was assessed by
color flow Doppler, continuous-wave Doppler, and pulsed-wave
Doppler ultrasonography. The echocardiographic grading of AI
was as follows: 0 = none; 1+ = trace; 2+ = mild; 3+ = moderate;
and 4+ = severe. All studies were recorded on individual tapes in
chronologic sequence. The diameters of the sinotubular junction
and aortic anulus were measured retrospectively in all studies of all
patients in whom AI of more than 1+ developed. A random sample
of patients without AI with follow-up of the same duration or
longer had those diameters measured for comparison.
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Follow-up extended from 4 to 9 years, mean of 5.8 years, and
was complete.
Statistical Analysis
The primary end point for the study was the development of AI of
more than 1+. Secondary end points included late survival and
freedom from adverse events such as structural valve deterioration,
reoperation, thromboembolic events, and prosthetic valve endo-
carditis.
SAS 6.12 for Windows was used for all statistical analyses
(SAS Institute, Inc, Cary, NC). Continuous variables are reported
as the mean ± 1 SD in tables and text and as the mean ± 1 SE in
figures unless otherwise noted.
Baseline and operative comparisons between groups (AI>1+ vs
no AI) for continuous variables were performed with the use of
unpaired t tests and the χ2 or Fisher exact test (where appropriate)
for categorical variables. Late survival and freedom from adverse
events were estimated by the nonparametric Kaplan-Meier
method. The log-rank test was used for statistical comparisons of
the Kaplan-Meier curves. There were too few events to develop a
stable multivariable Cox model for predictors of AI more than 1+.
Evaluations of echocardiographic diameters were made by
analysis of covariance testing the main effects, AI group, year, and
the interaction of AI group times year. For statistical corroboration
we also used the SAS procedure PROC MIXED to test the same
main effects. A 1-way analysis of variance was used to test differ-
ences in echocardiographic diameters between AI grades.
Results
Table 1 shows the clinical profile and operative data of the
patients in this study.
Aortic Insufficiency
AI of more than 1+ developed in 19 (11%) of 174 patients
during the follow-up period. Mild AI (2+) developed in 13
patients, moderate AI (3+) developed in 4, and severe AI
(4+) developed in 2 patients. In 80% of patients in whom AI
of more than 1+ developed, it did so during the first 4 years
of follow-up. Ninety-four percent of the entire patient sam-
ple has been followed up for longer than 4 years. Table 2
shows the clinical profile of patients with AI of more than
1+ and of the random patients without AI used for compar-
ison. Table 3 depicts the mean ± SD of the various diameter
ratios associated with each AI grade. There was a significant
difference between the AI grades by 1-way analysis for all
diameters and ratios with the exception of the aortic anulus
diameter.
Figure 1 shows the changes in the diameter of the sino-
tubular junction in patients with AI of more than 1+ and in
those without AI. This relationship showed a significant dif-
ference in slopes by analysis of covariance (P < .001).
Analysis of covariance also revealed a significant difference
in slope between the groups with AI of more than 1+ and the
non-AI groups over time for sinotubular junction/aortic anu-
lus (AI · Year, P = .031) and for sinotubular junction/valve
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size (AI · Year, P < .001). Analysis by a mixed model cor-
roborated that there was a significant difference in the slope
of the sinotubular junction/valve size relationships over time
(AI · Year, P = .001) and a significant difference between the
AI groups for the sinotubular junction/aortic anulus rela-
tionship (P < .001).
No predictors of dilation of the sinotubular junction
could be identified.
Clinical Outcomes
No operative deaths occurred, but there were 21 deaths dur-
ing the follow-up period: 2 valve-related (1 endocarditis and
1 stroke), 3 cardiac (1 sudden, 1 myocardial infarction, and
1 right-sided heart failure), and 16 due to other causes,
mostly malignancy. The survival was 82% ± 4% at 8 years,
as illustrated in Figure 2. There were 13 thromboembolic
events: 7 strokes and 6 transient ischemic attacks. The free-
dom from thromboembolic events was 92% ± 2% at 8 years.
There were 2 cases of prosthetic valve endocarditis, 1
early and 1 late in a patient with AI of more than 1+. Both
patients were reoperated on; the patient with early endo-
carditis died. The freedom from prosthetic valve endocardi-
tis was 98% ± 1% at 8 years.
Structural valve deterioration developed in 5 patients.
Four patients with documented structural valve deteriora-
tion had dilation of the sinotubular junction. All 5 patients
were successfully reoperated on and found to have tears in
one or more aortic cusps. The freedom from structural
valve deterioration at 8 years was 93% ± 4% for all
TABLE 1. Clinical profile of patients with the Toronto SPV
bioprosthesis
No. of patients 174
Age (y)
Mean ± SD 63 ± 11
Range 32-80
Sex
Male 120 (69)
Female 54 (31)
NYHA functional class
I 14 (8)
II 77 (44)
III 66 (38)
IV 17 (9)
Associated diseases
Hypertension 66 (38)
Diabetes mellitus 21 (12)
Peripheral vascular disease 7 (4)
Infective endocarditis
Active 0
Healed 4 (2)
Previous aortic valve surgery 6 (3)
Aortic valve lesion
Stenosis 135 (78)
Insufficiency 13 (9)
Mixed 24 (14)
Left ventricular ejection fraction
>59% 76 (44)
40%-59% 73 (42)
20%-39% 23 (13)
<20% 2 (1)
Coronary artery disease 55 (32)
Aortic valve disease
Tricuspid calcific 84 (48)
Bicuspid 58 (33)
Rheumatic 9 (5)
Prosthetic valve dysfunction 6 (3)
Undetermined 17 (10)
Toronto SPV bioprosthesis
Size 21 mm 3 (2)
Size 23 mm 14 (8)
Size 25 mm 43 (25)
Size 27 mm 62 (35)
Size 29 mm 52 (30)
Coronary artery bypass 55 (32)
Aortic clamping time (min) 85 ± 23
Cardiopulmonary bypass time (min) 106 ± 29
NYHA, New York Heart Association. Percentages are shown in parentheses.
TABLE 2.  Clinical profile of patients with AI of more than 1+
and random patients without AI
AI >1+ No AI P value
No. of patients 19 23
Mean age (y) 59 ± 11 64 ± 9 .1
Bicuspid aortic valve 4 (21) 8 (35) .3
Aortic valve lesion
Stenosis 14 (74) 20 (87)
Insufficiency 3 (16) 1 (4)
Mixed 2 (10) 2 (9) .4
Hypertension 4 (21) 7 (30) .4
Coronary artery disease 15 (79) 16 (70) .6
Mean follow-up (y) 5.2 ± 2.5 7.5 ± 0.9 .001
TABLE 3. Doppler echocardiographic diameters by AI grade
Diameter (cm) AI 0 AI 1+ AI 2+ AI 3+ P value*
Aortic anulus 2.09 ± 0.2 2.09 ± 0.2 2.15 ± 0.1 2.28 ± 0.3 .09
Sinus 2.83 ± 0.3 2.91 ± 0.4 2.98 ± 0.2 3.30 ± 0.4 .003
STJ 2.61 ± 0.3 2.72 ± 0.3 2.83 ± 0.3 3.25 ± 0.4 <.001
Ascending aorta 3.17 ± 0.5 3.66 ± 1.3 3.48 ± 0.4 3.90 ± 0.6 <.001
STJ/AA 1.25 ± 0.1 1.30 ± 0.1 1.31 ± 0.1 1.43 ± 0.1 <.001
STJ/AV size 0.98 ± 0.1 0.99 ± 0.1 1.04 ± 0.1 1.16 ± 0.1 <.001
Values are mean ± SD. AI, Aortic insufficiency grade; STJ, sinotubular
junction; STJ/AA, ratio of STJ/aortic anulus; STJ/AV size, ratio of STJ/size
of aortic valve prosthesis. AI 4+ developed in only 2 patients; therefore,
their estimates are not given.
*P value for 1-way analysis of variance for differences between AI grades.
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patients, 99% ± 1% for those without AI and 82% ± 12%
for those with AI of more than 1+ (P = .004), as shown in
Figure 3.
Eight patients have required repeat AVR: 2 for endo-
carditis, 5 for primary tissue failure, and 1 for AI due to dila-
tion of the sinotubular junction without primary tissue
failure. The freedom from repeat AVR at 8 years was 92% ±
4% for all patients, 97% ± 12% for those without AI, and
82% ± 12% for those with AI of more than 1+ (P = .02), as
shown in Figure 4.
At the last follow-up contact, 153 patients were alive:
81% were asymptomatic, 19% were in New York Heart
Association functional class II, and no patient was in class
III or IV. No patient was taking warfarin sodium, and none
has had hemorrhagic complications.
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Discussion
AVR with stentless porcine aortic valves has provided
excellent clinical outcomes.7-9 The hemodynamic perfor-
mance of these valves has also been excellent and appears to
be better than that of stented porcine aortic valves and sim-
ilar to that of aortic valve homografts.10,11 Indeed, most
patients have normal or near normal left ventricular mass
and function at 5 years postoperatively.7 These findings may
explain the apparent advantage in late survival after AVR
with stentless valves.9,12 We compared the survival after
AVR with stented and stentless valves in a case-match study
and found better survival in patients with stentless valves.9
The reduction in late deaths was largely due to fewer cardiac
deaths in the stentless group.9 Coincidentally, in this present
series there were 21 late deaths but only 5 were cardiac or
Figure 1. Changes in the diameter of the sinotubular junction in
patients with AI of more than 1+ (AI>1+) and in those without AI
(No AI). Analysis of covariance, AI · Year, P < .001.
Figure 3. Freedom from structural valve deterioration (SVD) in
patients with AI of more than 1+ (AI>1+) and in those without AI
(No AI).
Figure 4. Freedom from reoperation in patients with AI of more
than 1+ (AI>1+) and in those without AI (No AI). 
Figure 2. Survival after AVR with the Toronto SPV bioprosthesis.
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valve-related. These observations have been the main impe-
tus for us to continue using stentless biologic valves, partic-
ularly in patients with impaired left ventricular function.
The Toronto SPV bioprosthesis has been used clinically
only for a decade. This valve has exceptionally good hemo-
dynamics.7 However, we found that AI of more than 1+
developed in 11% of our patients during the first 8 years of
follow-up. Because dilation of the sinotubular junction
causes AI in patients with normal aortic valve cusps,1-4 we
reviewed all echocardiograms on the 19 patients in whom
AI of more than 1+ developed and measured the diameters
of the aortic anulus, aortic sinuses, sinotubular junction, and
ascending aorta. These diameters were compared with those
of a random sample of 23 patients without AI, as shown in
Table 3. The development of AI correlated with dilation of
the sinotubular junction in most patients. We believe that
dilation of the sinotubular junction preceded the develop-
ment of AI, because the aortic cusps had no evidence of
degeneration in any of the patients with AI graded as 2+ and
in 1 of the patients with 3+ AI. We could not identify any
factor predictive of dilation of the sinotubular junction,
probably because of the relatively small number of patients.
We expected to find that dilation of the sinotubular junction
would have been more common in patients with bicuspid
aortic valve disease, but this was not the case. Systemic
hypertension was not a predictor either.
Dilation of the sinotubular junction pulls the commis-
sures of the aortic valve apart, preventing the cusps from
coapting, and causes central AI. The native aortic valve does
not become incompetent with minor dilation of the sino-
tubular junction because the cusps are elastic and compen-
sate for the increase in distance between the commissures.
However, glutaraldehyde-fixed aortic cusps are relatively
inelastic and cannot compensate for the dilation. The lack of
coaptation of the cusps caused by the dilation of the sino-
tubular junction increases the mechanical stress with result-
ing premature valve failure. Indeed, among 5 patients
reoperated on for structural valve deterioration, gross dila-
tion of the sinotubular junction was present in 4. One addi-
tional patient was reoperated on because of moderate AI due
to dilation of the sinotubular junction, and the aortic cusps
were intact.
Dilation of the sinotubular junction is not specific to
AVR with the Toronto SPV bioprosthesis. Jin and Westaby13
described an identical problem after AVR with the
Medtronic Freestyle valve (Medtronic, Inc, Minneapolis,
Minn) and noted progressively more severe AI as the sino-
tubular junction diameter increased postoperatively.
Dilation of the sinotubular junction also occurs after aortic
root replacement with pulmonary autografts.5 We believe
we have resolved the problem of dilation of the sinotubular
junction of the pulmonary autograft in the aortic position by
banding the sinotubular junction with a strip of synthetic
fabric. Hence, banding of the sinotubular junction in
patients who have AVR with the Toronto SPV bioprosthesis
should prevent dilation of the sinotubular junction. A strip
of polyester fabric 4 to 5 mm wide should be used to band
the aorta at the level of the sinotubular junction and should
be secured to the posts of the Toronto SPV valve with inter-
rupted sutures to avoid its migration. The diameter of this
band should be identical to that of the valve implanted.
Banding of the sinotubular junction may enhance the dura-
bility of the Toronto SPV bioprosthesis by preventing dila-
tion of the sinotubular junction.
AVR with stentless valves is a technically more demand-
ing operation than AVR with stented valves. When a stentless
valve is used, many surgeons believe that a full root replace-
ment is preferable to reduce the risk of postoperative AI,
regardless of the type of stentless biologic valve used.14-17
Although this may be so, we believe that aortic root replace-
ment should be reserved for patients who have aortic root
disease. The majority of older patients who need AVR have
normal or near normal aortic root geometry and only the
cusps are diseased. If a stentless porcine valve is used in
these patients, the technique of subcoronary implantation is
probably the safest one. Surgical removal of the Toronto
SPV valve is not more complex than removal of any stented
aortic valve. Seven of 8 patients who have required repeat
AVR were operated by us without operative death or serious
complication. To re-replace an aortic root is a far more com-
plex operation.
Limitations of the Study 
The number of patients in whom AI developed is relatively
small in this study. Because moderate or severe AI devel-
oped in only 6 patients, we had to include those who had
mild AI to demonstrate that dilation of the sinotubular junc-
tion is the principal cause of late postoperative AI. In addi-
tion, we could not prove that dilation of the sinotubular
junction was the cause of AI, and it is conceivable, albeit
unlikely, that AI caused dilation of the sinotubular junction.
In summary, 11% of patients who underwent AVR with
the Toronto stentless porcine valve had AI of more than 1+.
AI was strongly associated with dilation of the sinotubular
junction, resulting in an increased risk of premature valve
failure and reoperation. Banding the sinotubular junction
may prevent dilation and enhance the durability of this valve.
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Discussion
Dr Neal Kon (Winston-Salem, NC). Dr David has been a pio-
neer in the use of stentless porcine aortic valves. He introduced
them into his clinical practice in the early 1980s and demonstrated
their huge hemodynamic advantage. He later showed that these
hemodynamic benefits result in significant left ventricular mass
reduction, which translated into improved quality of life and sur-
vivals for his patients. Dr David has also taught us through his
work with aortic root remodeling that the aortic valve consists not
only of aortic valve leaflets, but also the aortic anulus, the sinuses
of Valsalva, and the sinotubular junction. It is the appropriate geo-
metric relationship of all these components that results in a com-
petent aortic valve. 
When using a subcoronary implant technique, achieving these
geometric relationships perfectly can be difficult. It is necessary to
replace just the leaflets, so one must now place new porcine cusps
appropriately in a human foreign root. Even if one does this perfectly,
which can be difficult, the aortic root, and particularly the sinotubu-
lar junction, has a tendency to change with time. Dr David told me
that every 10 years the sinotubular junction dilates about 2 mm. 
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Eleven percent of the patients in this study had mild or greater
AI. The development of significant AI was associated with dilation
of the sinotubular junction. 
Dr David has shown us a potential problem with the subcoro-
nary implantation technique, which may lead to premature valve
failure. He also proposes a cure, the cure being placing a Dacron
band around the sinotubular junction at the time of implantation to
prevent dilatation. I agree with this problem but I am not sure I
agree with the cure. 
We have used a short aortic root replacement, which is proba-
bly better called a total AVR, as the technique of choice for stent-
less valve implantation. We use this technique regardless of the
presence or absence of root disease.
In 7 years of follow-up, no patient has had more than trivial AI,
and there has been no increase in gradients over time. Also, the
sinotubular junction, the aortic anulus, and the sinus of Valsalva
measurements do not change with time when a short root replace-
ment is done. 
Dr David, I have 2 questions for you. First, why not use a short
root replacement technique instead of banding the sinotubular
junction when the life expectancy of the patient is less than 15
years and when the native aortic root is not symmetrical? Do you
predict that the more perfectly you implant the stentless valve,
since this can be variable with stentless valves, the better the dura-
bility will be? 
Second, when a surgeon slightly oversizes a stentless valve and
uses a subcoronary technique, allowing a little extra leaflet coap-
tation on the chance that AI might develop, will that valve fail
prematurely as well? 
Dr David. Thank you, Dr Kon. I think your comments are very
appropriate and I appreciate your questions. I do not know whether
aortic root replacement or subcoronary implantation is better when
a stentless porcine valve is used. Being a student, I will continue
to look into this matter with interest. There are not enough data in
the literature on operative mortality for aortic root re-replacement.
My bet is that mortality is not 1% or 2%. If it is 20% or 30%, then
implantation of a stentless valve in the subcoronary position would
be safer as the first procedure because the operative risk of replac-
ing these valves is low when performed electively. Even if a
Dacron band were placed on the sinotubular junction, it would not
be difficult to reoperate on these patients. 
A porcine xenograft aortic root may function very well when
used for aortic root replacement. However, this is not always the
case when an aortic homograft or pulmonary autograft is used. We
are seeing the same incidence of AI after aortic root replacement
with aortic homografts or pulmonary autografts that we see with
stentless porcine valves in the subcoronary position at 8 to 10
years of follow-up. My bet is that they dilate too. We have already
documented this problem with the Ross procedure. 
The second question concerns oversizing a stentless valve.
Although I did do that some 5 to 10 years ago, we have now
learned that this is probably a mistake. It is better to use a valve the
size of the anulus and adjust the sinotubular junction to the size of
the valve. Oversizing, particularly xenograft tissue, causes bends
on the cusps, and those bends eventually tear or calcify prema-
turely. There is experimental work proving that already.
